1Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes:a patient centered approach Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012.35,1364-1379.
2lnzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012,55:1577 1596.
3Stratton IM, Adler AI, Nell HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321:405-412.
4UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998 352:837 853.
5Holman RR, Paul SK, Bethel MA, Matthews DR, Neff HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359:1577 1589.
6Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358:2545-2559.
7Vasilakou D, Karagiannls T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review andmetaanalysis. Ann Intern Med, 2013 159:262-274.
8StenlSf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab, 2013, 15:372 382.
9Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52 week randomized trial. Diabetes Care 2013, 36:2508-2515.
10Roden M, Weng J, Eilbracbt J, et al. EMPAREG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol, 2013, 1:208-219.
